Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02471690 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a New Formulation of Oritavancin in Healthy Volunteers
A Phase 1 study, sponsored by The Medicines Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT02471690: Completed Phase 1 study, sponsored by The Medicines Company.
NCT02471690 is a Phase 1 study that has completed, run by The Medicines Company. The registered enrollment target is 56 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02471690, a Phase 1 study, has completed, sponsored by The Medicines Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
The protocol describes a double-blind study to evaluate the Pharmacokinetics and safety of a new formulation of oritavancin by adjusting infusion time, concentration and reconstitution/administration solutions, of a single 1200 mg intravenous (IV) infusion of oritavancin
Primary Outcome
A composite measure of the number and types of AE/SAEs encountered and relationship to time of dosing
Interventions
- DRUG Dextrose
- DRUG Oritavancin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2015-07 |
| Est. Completion | 2016-04 |
| Phase | Phase 1 |
What the finished NCT02471690 record still lists
NCT02471690 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Dextrose is the first listed.
NCT02471690 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02471690 about?
NCT02471690 is a clinical study titled "Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a New Formulation of Oritavancin in Healthy Volunteers". The protocol describes a double-blind study to evaluate the Pharmacokinetics and safety of a new formulation of oritavancin by adjusting infusion time, concentration and reconstitution/administration solutions, of a single 1200 mg intravenous (IV) infusion of oritavancin
What is the current status of trial NCT02471690?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2015-07. Estimated completion is 2016-04.
What interventions are being tested in trial NCT02471690?
The interventions under investigation include: Dextrose (DRUG), Oritavancin (DRUG).
Who is sponsoring clinical trial NCT02471690?
This trial is sponsored by The Medicines Company, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02471690's enrollment target sits among peer trials
56 902nd of 2000 higher than 1,083 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia